<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00927095</url>
  </required_header>
  <id_info>
    <org_study_id>MH081837</org_study_id>
    <secondary_id>R01MH081837</secondary_id>
    <nct_id>NCT00927095</nct_id>
  </id_info>
  <brief_title>Continuous Oral Contraceptive Treatment in Premenstrual Dysphoric Disorder (PMDD)</brief_title>
  <acronym>PMDD</acronym>
  <official_title>Continuous OC Treatment in PMDD: Steroid Hormone Mechanisms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare a low dose oral contraceptive (OC) given continuously
      (every day for three months) with the same low dose oral contraceptive given in an
      interrupted regimen (one week of inactive placebo pills each month) and with continuous
      placebo (inactive placebo given every day for three months). The primary hypothesis is that
      continuous OC will be significantly more effective in reducing premenstrual symptoms compared
      with either the interrupted OC or continuous placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Premenstrual Dysphoric Disorder (PMDD) describes the cyclic appearance of affective symptoms
      and resultant impairment during the luteal phase of the menstrual cycle. The objective of
      this trial is to determine if extended oral contraceptive (OC) regimens with eliminated
      pill-free intervals will successfully prevent the expression of PMDD symptoms. The central
      hypothesis of this application is that continuous administration of OCs will minimize the
      destabilizing effects of changing reproductive steroid levels and prevent PMDD symptom
      emergence. The cause of PMDD is unknown, the morbidity substantial, and the identified
      treatments limited in their effectiveness, since 40% of PMDD women are non-responders to
      elective serotonin re-uptake inhibitors (SSRIs). Earlier controlled studies of OCs to treat
      PMDD failed to find OCs superior to placebo using the traditional 21/7 platform (21 active
      pills followed by a 7 day pill-free interval (PFI)). Two recent trials of a low dose OC using
      a 24/4 platform did report greater reductions in premenstrual symptoms relative to placebo,
      presumably due to the shortened PFI. Despite the apparent efficacy of the 3-day extended
      dosing of this OC, the placebo response rate was substantial in these studies, resulting in a
      low effect size. Moreover, no steroid hormone levels were examined in these prior studies. In
      the absence of hormonal data, inferences about the mechanism of efficacy of extended OCs must
      remain speculative and untested.

      Our proposed research will addresses the critical role of hormonal change in the
      precipitation of PMDD symptoms before and after treatment with a continuous OC regimen, an
      interrupted OC regimen (21/7 platform) and continuous placebo. This study will also permit us
      to examine the role of neurosteroids in PMDD. While acting acutely as anxiolytic positive
      modulators of the gamma-aminobutyric acid A (GABAA) receptor, these neurosteroids may
      paradoxically reduce the response of the GABAA receptor and cause irritability (in rats)
      following either extended exposure or withdrawal. Further, our prior research suggests that
      elevated levels of or changes in peripheral neurosteroid levels are associated with dysphoric
      mood symptoms in women with PMDD. Our hypothesis is that changes in neurosteroids modulate
      symptom severity rather than appearance in PMDD. The results of our study will suggest
      therapeutic targets and will inform future studies of both PMDD and related affective
      disorders.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pre-Post Change in Premenstrual Symptom Severity</measure>
    <time_frame>monthly</time_frame>
    <description>Pre-post change (pre minus post) in mean premenstrual week severity of the worst emotional symptom as measured using the Daily Record of Severity of Problems items 1-8. Worst symptom for each individual was defined as the symptom in the baseline month demonstrating the highest mean severity during the premenstrual week. Mean premenstrual week severity scores were calculated to correspond to mean ratings; therefore, the mean premenstrual severity values ranged as follows: 1=Not at All, 2=Minimal, 3=Mild, 4=Moderate, 5=Severe, 6=Extreme. The change variable presented here is calculated as follows: &quot;mean rating on the individual's worst symptom during the premenstrual week at baseline&quot; minus &quot;mean rating during the premenstrual week during the last on-treatment cycle&quot;. Therefore, higher values on this outcome variable correspond to greater reductions in premenstrual symptoms across the trial.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">67</enrollment>
  <condition>Premenstrual Dysphoric Disorder</condition>
  <arm_group>
    <arm_group_label>Continuous OC (EE/DROS)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Continuous daily oral drospirenone (DROS; 3mg) + ethinyl estradiol (EE; 20ug)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intermittent OC (EE/DROS)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Interrupted (21 days active - 7 days placebo) oral DROS (20ug)/EE(3mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Continuous daily oral placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Continuous OC (EE/DROS)</intervention_name>
    <description>Continuous EE(20ug)+DROS(3mg) daily for 3 months</description>
    <arm_group_label>Continuous OC (EE/DROS)</arm_group_label>
    <other_name>Yaz</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intermittent OC (EE/DROS)</intervention_name>
    <description>Intermittent EE(20ug)+DROS(3mg) daily for 21 days each month</description>
    <arm_group_label>Intermittent OC (EE/DROS)</arm_group_label>
    <other_name>Yaz</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>daily placebo</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>oral placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  meets prospective criteria for PMDD, AND

          -  English speaking and reading skills.

        Exclusion Criteria:

          -  current psychiatric disorder other than PMDD,

          -  history of venous thromboembolism,

          -  over 35 years of age and obese,

          -  uncontrolled hypertension or end-organ vascular disease,

          -  diabetes,

          -  migraine headache with aura,

          -  breastfeeding or pregnant,

          -  cigarette smoking,

          -  family history of premenopausal breast cancer or breast cancer in more than one first
             degree relative,

          -  elevated serum potassium levels, use of prescription medications (except stable
             thyroid supplementation),

          -  irregular menstrual cycles, OR

          -  history of: endometriosis, hepatic disease, breast carcinoma, pulmonary embolism or
             phlebothrombosis, malignant melanoma, cholecystitis or pancreatitis.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>52 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan Girdler, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina, Chapel Hill</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 22, 2009</study_first_submitted>
  <study_first_submitted_qc>June 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2009</study_first_posted>
  <results_first_submitted>April 25, 2016</results_first_submitted>
  <results_first_submitted_qc>July 13, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 24, 2016</results_first_posted>
  <last_update_submitted>July 13, 2016</last_update_submitted>
  <last_update_submitted_qc>July 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of North Carolina, Chapel Hill</investigator_affiliation>
    <investigator_full_name>Susan Girdler, PhD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>PMDD</keyword>
  <keyword>Oral contraceptives</keyword>
  <keyword>steroid hormones</keyword>
  <keyword>neurosteroids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premenstrual Dysphoric Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Contraceptives, Oral</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Continuous Low Dose Oral Contraceptive</title>
          <description>continuous low dose oral contraceptive
low dose oral contraceptive (20 ug ethinyl estradiol + 3 mg drospirenone): daily for three months</description>
        </group>
        <group group_id="P2">
          <title>Interrupted Low Dose Oral Contraceptive (21/7 Platform)</title>
          <description>interrupted low dose oral contraceptive (21/7 platform)
20 ug ethinyl estradiol + 3 mg drospirenone: daily for 21 days each month</description>
        </group>
        <group group_id="P3">
          <title>Continuous Placebo</title>
          <description>continuous placebo
placebo: daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Continuous Low Dose Oral Contraceptive</title>
          <description>continuous low dose oral contraceptive
low dose oral contraceptive (20 ug ethinyl estradiol + 3 mg drospirenone): daily for three months</description>
        </group>
        <group group_id="B2">
          <title>Interrupted Low Dose Oral Contraceptive (21/7 Platform)</title>
          <description>interrupted low dose oral contraceptive (21/7 platform)
20 ug ethinyl estradiol + 3 mg drospirenone: daily for 21 days each month</description>
        </group>
        <group group_id="B3">
          <title>Continuous Placebo</title>
          <description>continuous placebo
placebo: daily</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="24"/>
            <count group_id="B4" value="67"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.2" spread="8.1"/>
                    <measurement group_id="B2" value="32.2" spread="8.6"/>
                    <measurement group_id="B3" value="32.1" spread="6.7"/>
                    <measurement group_id="B4" value="32.5" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pre-Post Change in Premenstrual Symptom Severity</title>
        <description>Pre-post change (pre minus post) in mean premenstrual week severity of the worst emotional symptom as measured using the Daily Record of Severity of Problems items 1-8. Worst symptom for each individual was defined as the symptom in the baseline month demonstrating the highest mean severity during the premenstrual week. Mean premenstrual week severity scores were calculated to correspond to mean ratings; therefore, the mean premenstrual severity values ranged as follows: 1=Not at All, 2=Minimal, 3=Mild, 4=Moderate, 5=Severe, 6=Extreme. The change variable presented here is calculated as follows: &quot;mean rating on the individual's worst symptom during the premenstrual week at baseline&quot; minus &quot;mean rating during the premenstrual week during the last on-treatment cycle&quot;. Therefore, higher values on this outcome variable correspond to greater reductions in premenstrual symptoms across the trial.</description>
        <time_frame>monthly</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Continuous Low Dose Oral Contraceptive</title>
            <description>continuous low dose oral contraceptive
low dose oral contraceptive (20 ug ethinyl estradiol + 3 mg drospirenone): daily for three months</description>
          </group>
          <group group_id="O2">
            <title>Interrupted Low Dose Oral Contraceptive (21/7 Platform)</title>
            <description>interrupted low dose oral contraceptive (21/7 platform)
20 ug ethinyl estradiol + 3 mg drospirenone: daily for 21 days each month</description>
          </group>
          <group group_id="O3">
            <title>Continuous Placebo</title>
            <description>continuous placebo
placebo: daily</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-Post Change in Premenstrual Symptom Severity</title>
          <description>Pre-post change (pre minus post) in mean premenstrual week severity of the worst emotional symptom as measured using the Daily Record of Severity of Problems items 1-8. Worst symptom for each individual was defined as the symptom in the baseline month demonstrating the highest mean severity during the premenstrual week. Mean premenstrual week severity scores were calculated to correspond to mean ratings; therefore, the mean premenstrual severity values ranged as follows: 1=Not at All, 2=Minimal, 3=Mild, 4=Moderate, 5=Severe, 6=Extreme. The change variable presented here is calculated as follows: &quot;mean rating on the individual's worst symptom during the premenstrual week at baseline&quot; minus &quot;mean rating during the premenstrual week during the last on-treatment cycle&quot;. Therefore, higher values on this outcome variable correspond to greater reductions in premenstrual symptoms across the trial.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.93" spread=".22"/>
                    <measurement group_id="O2" value="1.73" spread=".22"/>
                    <measurement group_id="O3" value="1.64" spread=".19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Continuous Low Dose Oral Contraceptive</title>
          <description>continuous low dose oral contraceptive
low dose oral contraceptive (20 ug ethinyl estradiol + 3 mg drospirenone): daily for three months</description>
        </group>
        <group group_id="E2">
          <title>Interrupted Low Dose Oral Contraceptive (21/7 Platform)</title>
          <description>interrupted low dose oral contraceptive (21/7 platform)
20 ug ethinyl estradiol + 3 mg drospirenone: daily for 21 days each month</description>
        </group>
        <group group_id="E3">
          <title>Continuous Placebo</title>
          <description>continuous placebo
placebo: daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GI Symptoms</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="22"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="21"/>
                <counts group_id="E3" events="13" subjects_affected="13" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Bloating</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="21"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Heartburn or Reflux</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="22"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="21"/>
                <counts group_id="E3" events="15" subjects_affected="15" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Yeast Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Leg or Calf Discomfort</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="22"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="21"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache, Not Migraine</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="22"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="21"/>
                <counts group_id="E3" events="20" subjects_affected="20" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Headache, Migraine, No Aura</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="22"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Headache, Migraine, with Aura</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Low Mood</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="22"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="21"/>
                <counts group_id="E3" events="17" subjects_affected="17" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="22"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="21"/>
                <counts group_id="E3" events="15" subjects_affected="15" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Anxious Symptoms</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="22"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="21"/>
                <counts group_id="E3" events="15" subjects_affected="15" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Suicidality</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast Tenderness</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="22"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="21"/>
                <counts group_id="E3" events="18" subjects_affected="18" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Spotting</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="22"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="21"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Changing Bleeding Pattern - Prolonged Bleeding</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="22"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Change in Bleeding Pattern</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Shortness of Breath or Chest Pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Susan Girdler</name_or_title>
      <organization>University of North Carolina at Chapel Hill</organization>
      <phone>919-966-2179</phone>
      <email>susan_girdler@med.unc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

